Discontinued — last reported Q3 '25
West Pharmaceutical Services Impairment Charges remained flat by 0.0% to $300.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $300.00K to $300.00K. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase signals poor past investment decisions or deteriorating market conditions, which is generally viewed negatively by investors.
These are non-cash charges recognized when the carrying value of an asset exceeds its fair market value. Such charges in...
Common in large, diversified firms that frequently acquire or divest business units.
impairment_charges| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $200.00K | $200.00K | $0.00 | $200.00K | $1.40M | $1.90M | $1.50M | $3.50M | $600.00K | $300.00K | $1.00M | $300.00K | $3.80M | $300.00K | $300.00K |
| QoQ Change | — | +0.0% | -100.0% | — | +600.0% | +35.7% | -21.1% | +133.3% | -82.9% | -50.0% | +233.3% | -70.0% | >999% | -92.1% | +0.0% |
| YoY Change | — | — | — | +0.0% | +600.0% | — | +650.0% | +150.0% | -68.4% | -80.0% | -71.4% | -50.0% | >999% | -70.0% | +0.0% |
| Segment | Q1 '23 |
|---|---|
| Proprietary Products | $9.40M |
| Total | $1.90M |
Proprietary Products was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.